A Study Evaluating the Safety and Efficacy of BEAM-201 in Relapsed/Refractory T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LL)
Lymphoblastic Lymphoma · T-Cell Lymphoblastic Leukemia/Lymphoma · Lymphoblastic Leukemia
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 1/2
- Patients
- 5 (final count)
- Started
- May 25, 2023
- Main results expected
- Dec 2026
- Fully finished
- Dec 2026
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
Incidence and severity of treatment-emergent adverse events (TEAEs) and treatment-related adverse events, including serious adverse events (SAEs) and dose-limiting toxicities (DLTs; in Phase 1 only)
Measured over: Through study completion, an average of 25 months
Overall response rate as defined as proportion of T-ALL patients achieving complete response (CR) or complete response with incomplete hematologic recovery (CRi) or T-LL patients achieving CR or PR at any point after BEAM-201 infusion
Measured over: From treatment with BEAM-201 through study completion
Changes Tremor has spotted
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT05885464 · record last updated 2025-01-13 · checked 2026-11-09 15:47 UTC